Quantum BioPharma Ltd Stock Price, News & Analysis

Quantum BioPharma (NASDAQ: QNTM) has announced positive results from its Phase 1 Multiple Ascending Dose (MAD) clinical trial for Lucid-MS, their experimental multiple sclerosis drug. The Clinical Study Report (CSR) confirms that Lucid-MS demonstrated safety and tolerability in healthy participants with consecutive daily dosing.

Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound designed to prevent demyelination, a characteristic feature of multiple sclerosis. The successful completion of this trial and CSR marks a crucial milestone, enabling the company to proceed with its Investigational New Drug (IND) application to the FDA and advance toward efficacy trials in MS patients.

Quantum BioPharma (NASDAQ: QNTM) has filed a memorandum of law opposing CIBC World Markets and RBC Dominion Securities' joint motion to dismiss in the Southern District of New York. The lawsuit alleges that the defendants engaged in market manipulation through "spoofing" between January 2020 and August 2024, seeking damages exceeding $700 million USD.

The company claims its stock traded above $460 USD per share in January 2020 with a market cap approaching $1 billion before being artificially depressed. Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis, eliminating material financial pressure on Quantum. The company suggests other banks may be involved but will refrain from naming them until gathering more conclusive evidence.

Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has launched a Regulation D 506(c) offering to raise up to $5.0 million. The capital raise will fund growth initiatives and establish a path toward a potential IPO, without diluting Quantum BioPharma shareholders.

Quantum BioPharma maintains a 25% ownership stake in Unbuzzd through an anti-dilution provision until Unbuzzd reaches a $1 billion valuation. Unbuzzd has partnered with MZ Digital and Dealmaker for the capital raise campaign, accepting both traditional and cryptocurrency payments through ALT5 Pay's platform.

Unbuzzd is led by CEO John Duffy, former Coca-Cola VP, and Board Co-Chair Gerry David, former CEO of Celsius Holdings. The company produces unbuzzd™, a functional beverage designed to accelerate alcohol metabolism and reduce hangover symptoms.

Quantum BioPharma (NASDAQ: QNTM) has announced a strategic investment in GameStop Corp. (NYSE: GME), purchasing 2,000 shares. This move is part of the company's broader strategy to combat market corruption and enhance shareholder value. The company has recently appointed anti-market manipulation advocates including Kevin Malone as Board Advisor and Terry Lynch as Director.

The company is pursuing legal action against CIBC World Markets and RBC Dominion Securities, seeking damages exceeding $700 million USD for alleged stock manipulation. Additionally, Quantum completed a debt settlement of US$40,000 through the issuance of Class B shares. Malone Wealth Ventures, LLC, which owns approximately 21.8% of Quantum's Class B shares, received 30,000 shares and 60,000 RSUs as consulting compensation.

Quantum BioPharma (NASDAQ: QNTM) has submitted its patented drug candidate Lucid-21-302 (Lucid-MS) to the UK's Innovative Licensing and Access Pathway (ILAP) Passport program. The drug represents a first-in-class treatment for multiple sclerosis, specifically targeting demyelination.

The ILAP program is designed to accelerate the development and approval process of innovative medicines through collaboration between medicine developers, the MHRA, health assessment bodies, NHS, and patients. This submission marks the first step in potentially fast-tracking the drug's development and approval process in the UK.

Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has launched a $5 million Regulation D 506(c) capital raise to fund growth and prepare for a potential IPO. The company has engaged MZ Digital for marketing and Dealmaker as the crowdfunding platform.

Unbuzzd produces a scientifically-proven beverage that accelerates alcohol metabolism and reduces hangover symptoms. The company is led by CEO John Duffy, former Coca-Cola VP, and Board Co-Chair Gerry David, former CEO of Celsius Holdings. The funds will support direct-to-consumer, distributor, and retail expansion plans.

Quantum BioPharma (NASDAQ: QNTM) has announced the first successful scan of a multiple sclerosis (MS) patient in a joint study with Massachusetts General Hospital (MGH). The study utilizes a novel PET tracer [18F]3F4AP to monitor myelin integrity and demyelination in MS patients. The scanning was performed using a new GE Signa PET-MR scanner, which allows simultaneous PET and MRI imaging, improving spatial and temporal coregistration while reducing patient scan time. This imaging technique could potentially serve as a biomarker to measure the effectiveness of drugs like Quantum's investigational MS drug Lucid-21-302. The PET tracer, developed by Dr. Pedro Brugarolas at MGH, has shown promising results in previous animal and human studies, demonstrating high sensitivity to demyelinated lesions and favorable pharmacokinetics.

Quantum BioPharma (NASDAQ: QNTM) has announced plans to issue special dividend Contingent Value Rights (CVRs) to holders of Class B Subordinate Voting Shares on a 1:1 basis. The CVRs will entitle holders to receive between 10-50% of net proceeds from the company's ongoing litigation against major banks, including CIBC World Markets and RBC Dominion Securities. The litigation seeks damages exceeding $700 million related to alleged stock price manipulation. These CVRs will be non-transferable, non-interest bearing, without voting rights, and redeemable only if the company receives proceeds from the litigation settlement. The exact payout percentage and record date are yet to be determined, and the CVRs will not be listed on any exchange.

Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency investment portfolio to USD $5,000,000 through additional purchases of Bitcoin (BTC) and other digital currencies. The Board of Directors-approved investment demonstrates the company's strategic approach to using cryptocurrencies as both an investment vehicle and a hedge against the dollar. The company has established infrastructure to accept cryptocurrency-based financing and execute various transactions, with all digital assets being held by a compliant custodian. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions while ensuring full compliance with financial and audit regulations.